Skip to main content

Table 3 Potential biomarkers in cecal contents based on the UPLC-Q-TOF/MS analysis and the changes between different groups

From: Aspirin eugenol ester regulates cecal contents metabolomic profile and microbiota in an animal model of hyperlipidemia

SM RT VIP Metabolite Formula m/z Adduction Fold change Pathway
M/C AEE/M
+ 2.26 2.92 Hypoxanthine C5H4N4O 137.0459 [M + H]+ 0.39** 1.12 Purine metabolism
+ 18.11 2.04 Linoleic acid C18H32O2 281.2479 [M + H]+ 3.78** 0.81 Linoleic acid metabolism
+ 17.84 1.40 LysoPC(18:1(9Z)) C26H52NO7P 522.3606 [M + H]+ 1.90* 0.47* Glycerophospholipid metabolism
+ 19.32 1.01 Linoleoyl ethanolamide C20H37NO2 324.2905 [M + H]+ 1.59* 0.88
+ 21.26 2.51 Oleamide C18H35NO 282.2796 [M + H]+ 2.19* 0.49*
+ 14.81 8.12 Sphingosine C18H37NO2 300.2904 [M + H]+ 2.98** 0.52** Sphingolipid metabolism
2.99 1.07 Uridine C9H12N2O6 243.0622 [M-H]- 0.35** 1.14 Pyrimidine metabolism
10.40 1.17 Sebacic acid C10H18O4 201.1132 [M-H]- 0.49* 1.43
  1. SM scan model, RT retention time, VIP Variance importance for projection, LysoPC, Lysophosphatidylcholine, M/C: model versus control, AEE/M: AEE versus model, *P < 0.05, **P < 0.01 compared with corresponding group